Madrigal Pharmaceuticals (MDGL): The Widening Loss Is Exactly What You Want to See (Upgrade)

What more does the market want from Madrigal Pharmaceuticals?

Rezdiffra revenue jumped 71% year-over-year in the second quarter, beating consensus estimates. Earnings per share came in at a loss of a loss of $1.99 versus a projected loss of $2.23 to $2.55 — a beat on both revenue and EPS. Patient count more than doubled from a year ago to over 49,000, crossing 50,000 by early July. Trailing-12-month sales approached $1.3 billion for the first and only FDA-approved treatment of MASH (metabolic dysfunction–associated steatohepatitis, formerly NASH), a liver disease that afflicts millions in the United States.

Despite all that, the stock fell 9.8% on July 31st when the report landed. The headline trigger: the net loss widened from $42.3 million in Q2 2025 to $57.9 million this year.

I've been puzzled by the reaction. The market treated the widening loss as operational deterioration when the numbers tell the opposite story. Now the stock has bounced 9.1% over five days, as if the selling impulse exhausted itself. That's the kind of whiplash that usually marks a contrarian inflection.

The Widening Loss Wasn't What You Think

Here's what actually drove the higher net loss. The $25 million increase breaks down into three buckets, and only one reflects the kind of cost creep that should alarm you.

First, and largest: a one-time $25 million upfront payment to Arrowhead Pharmaceuticals for global rights to ARO-PNPLA3, a clinical-stage RNA interference therapy targeting the PNPLA3 gene mutation. This mutation is present in roughly 30% of MASH patients with moderate-to-advanced fibrosis and is especially prevalent among Hispanic patients. Phase I data showed a 46% reduction in liver fat from a single dose. The deal carries up to $975 million in milestones and tiered royalties. Writing a $25 million check to secure a potential combination partner for Rezdiffra is not a warning sign — it's the kind of strategic investment you expect from a company building a franchise, not just riding a single drug.

Second: cost of sales rose to $40 million from $9.1 million a year prior. That increase is almost entirely Roche royalties on higher Rezdiffra sales, plus a small inventory write-down. Royalties scale with revenue. If your product sells more, your cost of sales goes up. That's not an efficiency problem; it's the mechanics of a revenue-sharing license paying off as the drug takes off.

Third: SG&A increased from $196.9 million to $289.4 million. This is the real question mark. The rise reflects continued investment in the Rezdiffra commercial engine — the endocrinology field force expansion that began in the fourth quarter of 2025 and ongoing direct-to-consumer marketing. These costs are real and they're sticky. But they're also deliberate. You don't build a $46 billion addressable market on a hobbyist sales team.

Strip out the $25 million Arrowhead payment and the Q2 loss would have been approximately $33 million, versus $42.3 million a year ago. Operational losses actually narrowed. The market's focus on the headline loss number was, frankly, a category error.

The Revenue Engine Is What Matters

The headline loss distracted from what's structurally important: Rezdiffra's revenue trajectory is accelerating.

Q1 2026 brought $311.3 million (up 127% year-over-year). Q2 brought $364.3 million (up 71%). The sequential growth rate slowed as the base got larger, which is normal. But Q2 still beat the $349 million to $359 million consensus range, and management expressed comfort with consensus quarterly growth rates through the rest of 2026. H1 2026 revenue of $675.6 million puts the company on a run rate approaching $1.4 billion — a number that matters because it's being generated by a single product launched barely 16 months ago, with negligible international contribution.

Gross margins sit at 93%, which is textbook biopharma and means every additional dollar of sales flows directly to operating leverage. The diagnosed U.S. specialist-addressable market for F2/F3 MASH grew to approximately 460,000 at the end of 2025, up from 315,000 in 2023. Madrigal estimates roughly 10% diagnosis rates and 10% penetration among diagnosed patients. If those estimates hold, the current patient base of 50,000 represents early innings, not a peak.

The Moat: First, Alone, and Protected

Before calling the selloff overdone, the question is whether Rezdiffra's competitive position can survive the pressure. Here the evidence is clear.

Rezdiffra remains the only FDA-approved therapy for MASH. Yes, the approval is accelerated — meaning full approval depends on confirmatory data from the MAESTRO-NASH Phase III biopsy study, with results expected in 2028. That's a real overhang. But the company already has conditional approval in the EU, and it just received three new patents extending protection for F2-F3 MASH treatment into 2045 and for compensated cirrhosis (F4c) into 2042. The IP runway is long.

The pipeline strategy is defensible, not desperate. Madrigal is building combination therapies anchored by Rezdiffra — the oral GLP-1 MGL-2086 just started Phase I dosing in June, the Arrowhead PNPLA3 siRNA program targets a genetically defined subpopulation, and a DGAT-2 inhibitor and multiple other siRNA programs are queued for Phase II combination studies starting in 2027. The MAESTRO-NASH OUTCOMES trial in well-compensated cirrhosis patients is on track for a 2027 readout. This is a platform strategy, not a one-trick pony.

Competitors exist. Viking Therapeutics' VK2809 showed promising data in a head-to-head comparison. Novo Nordisk spent $5.2 billion acquiring Akero Therapeutics for its MASH program. But none of these companies currently have an approved, selling drug in this indication. First-mover advantage in a disease with low diagnosis rates and a slow-moving gastroenterology specialty is worth more than the market gives it credit for.

Valuation and The Disconnect

The stock trades at a market cap of $11.8 billion, or roughly 9.1 times trailing revenue. The enterprise value is $11.3 billion, or 8.8 times sales, after accounting for $839 million in cash and marketable securities. The company is still burning cash — free cash flow was negative $209 million over the trailing twelve months — so earnings multiples are meaningless for now. But for a company with 93% gross margins, 70%+ revenue growth, and the sole approved therapy in a market where the diagnosed addressable population is still expanding, the 8.8x EV/sales multiple is arguably a reflection of the accelerated-approval overhang, not the growth profile.

Cash at $839 million is a real buffer. The company burned approximately $150 million in the first half of 2026 (from $989 million at year-end 2025 to $839 million at quarter-end), which annualizes to roughly $300 million. That gives Madrigal well over two years of runway even if no dilution occurs. Management expects full-year R&D spending to be roughly in line with 2025 levels (including the Arrowhead upfront payment) and SG&A to increase. The cash position is comfortable, not existential.

Price Action: The Selloff Looked Exhausted

The stock fell 9.8% on July 31st despite the beat, then recovered 9.1% over the following five trading days to trade near $510. That kind of post-earnings whiplash — sharp rejection followed by rapid recovery — is a classic sign of selling exhaustion after a narrative-driven selloff. The stock sits at its 200-day moving average of $508 and just below its 50-day average of $515. The RSI at 47 is neutral, neither overbought nor oversold. Year-to-date, the stock is down 12.4%, well below its 52-week high of $615.

The price action suggests the bears got what they wanted on July 31st — a headline about a widening loss, a gap down, and a flush — and then couldn't sustain it. The 5-day recovery of 9.1% after the initial dump is the kind of pattern that usually marks a short-term bottom, not a distribution top.

The Real Risk

There is one structural risk that's worth sitting with. Accelerated approval means Madrigal must deliver confirmatory data from the MAESTRO-NASH Phase III study in 2028. If that study fails to meet its endpoints, Rezdiffra loses its U.S. market authorization. No amount of revenue growth or pipeline investment mitigates that binary risk. It's real, it's material, and investors who can't stomach it should stay away. But for those who believe in the drug's clinical profile and the strength of the Phase III design, the current price already discounts a meaningful probability of that outcome.

My Take

The market punished Madrigal for a net loss that widened because of a strategic licensing payment and expected commercial buildout — while revenue accelerated, EPS beat, and the patient base doubled. That's the kind of reaction that happens when the narrative outpaces the numbers.

I'm upgrading to a Buy. The risk/reward at $510 is attractive for a company with 93% gross margins, 70%+ revenue growth, the sole approved drug in an expanding disease area, and $839 million in cash. The better entries are on weakness near the 200-day average, not chasing above $550. I'd reassess if Q3 revenue growth slows below 50% year-over-year or if cash burn accelerates beyond the current trajectory. But as long as the patient count keeps climbing and the commercial engine builds, the market's focus on a headline loss number is missing the point.

Investors looking for a high-conviction growth setup in metabolic disease shouldn't let this buying opportunity go to waste.